Étiquette : traitement

Cannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability, Francesca Baratta et al., 2021

Cannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability Francesca Baratta, Marco Simiele, Irene Pignata, Lorenzo Ravetto Enri, Antonio D’Avolio, Riccardo Torta, Anna De Luca, Massimo Collino and Paola Brusa Pharmaceuticals, 2021, 14, 171, 1-13. Doi : 10.3390/ph14020171   Abstract : Current legislation in Italy provides that medical Cannabis may be administered orally or by inhalation. One of the fundamental criteria for the administration of oral formulations is that they deliver a known consistent quantity of the active ingredients to ensure uniform therapies leading to the optimisation of the risks/benefits. In 2018, our group developed an improved Cannabis oil extraction technique. The objective of [...]

Lire la suite

Cannabinoids Promising for Improving Appetite, Behavior in Dementia, Pauline Anderson, Medscape Medical News, 2021

Cannabinoids Promising for Improving Appetite, Behavior in Dementia Pauline Anderson Medscape Medical News © March 19, 2021 For patients with dementia, cannabinoids may be a promising intervention for treating neuropsychiatric symptoms (NPS) and the refusing of food, new research suggests. Results of a systematic literature review showed that cannabinoids were associated with reduced agitation, longer sleep, and lower NPS. They were also linked to increased meal consumption and weight gain. Refusing food is a common problem for patients with dementia, often resulting in worsening sleep, agitation, and mood, study investigator Niraj Asthana, MD, a second-year resident in the Department of Psychiatry, University of California, San Diego, told [...]

Lire la suite

Cannabidiol as an Intervention for Addictive Behaviors : A Systematic Review of the Evidence, Mélissa Prud’homme et al., 2015

Cannabidiol as an Intervention for Addictive Behaviors : A Systematic Review of the Evidence Mélissa Prud’homme, Romulus Cata and Didier Jutras-Aswad Substance Abuse : Research and Treatment,  2015, 9, 33-38. doi : 10.4137/SART.S25081.   Abstract : Drug addiction is a chronically relapsing disorder characterized by the compulsive desire to use drugs and a loss of control over consumption. Cannabidiol (CBD), the second most abundant component of cannabis, is thought to modulate various neuronal circuits involved in drug addiction. The goal of this systematic review is to summarize the available preclinical and clinical data on the impact of CBD on addictive behaviors. MEDLINE and PubMed were searched [...]

Lire la suite

Enfin la Justice pour les malades, Témoignage de Florence, La TéléLibre, 26 mars 2021

Publié le 26 mars 2021 | par La Rédac’ HISTORIQUE 🎉 ! Pour la première fois, dans une affaire d’usage de cannabis médical, la justice décide de la mise en place d’une expertise médicale au lieu de condamner à la prison et à une amende. Un cas qui devra faire jurisprudence. 🍾 LaTéléLibre était le seul média présent à l’audience pour ce tournant juridique qui fera date. Un scoop en fait…     Florence, atteinte par la maladie de Huntington a déjà témoigné à visage découvert sur LaTéléLibre. Elle nous avait expliqué comment les médicaments prescrits par ses médecins l’assommaient et l’empêchaient de mener [...]

Lire la suite

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, L.S. Kaertner et al., 2021

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, KAERTNER L.S., STEINBORN M.B., KETTNER H., SPRIGGS M.J., ROSEMAN L., BUCHBORN T., BALAET M., TIMMERMANN C., ERRITZOE D., CARHARDT-HARRIS R.L. : Nature, 2021, 11, 1941 Doi : 1038/s41598-021-81446-7   Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic [...]

Lire la suite

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD, Deborah Brauser, Medscape.com, 2021

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print   Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]

Lire la suite

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial, Elizabeth A. Thiele et al., 2020

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O'Callaghan, MBChB, PhD; MichaelWong,MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group JAMA Neurology, 2020, December 21 online, E1-E7. doi : 10.1001/jamaneurol.2020.4607   IMPORTANCE : Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as [...]

Lire la suite

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients, Diana M. Martinez, MD Medscape .com, 2020

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]

Lire la suite

Troubles anxieux : le CBD peut soulager les symptômes, Kalapa Clinic, 30/06/2020

Troubles anxieux : le CBD peut soulager les symptômes Kalapa Clinic, Barcelone, Espagne By Gesa|30/06/2020   La peur est une réaction naturelle à certaines situations et à certains événements. Elle remplit à la fois une fonction d’avertissement et de protection. Lors d’un trouble anxieux, cependant, elle développe une dynamique propre qui est très stressante pour les personnes concernées. Diverses études et rapports d’expérience indiquent que le cannabinoïde non-psychoactif cannabidiol (CBD) peut soulager leurs symptômes. En Allemagne, le trouble anxieux est la maladie mentale la plus courante, devançant même la dépression. Environ 12 millions de personnes sont touchées, les femmes plus souvent que les hommes (1). Le [...]

Lire la suite